Cipla Expands Women’s Health Portfolio through Acquisition of 4 Key Brands from Wanbury
Mumbai, India; February 07, 2020: Cipla Ltd. (BSE: 500087; NSE: CIPLA EQ; and hereafter referred to as “Cipla”) today announced the acquisition of nutrition products’ portfolio from Wanbury Ltd.Cipla has acquired 4 brands — CPink, CDense, Productiv and Folinine to further strengthen its presence in women’s health.
The nutraceutical products, to be sold under the 4 umbrella brands, would address various health needs for conditions arising due to nutritional deficiencies or insufficiencies. This includes supplements such as multivitamins, multimineral and antioxidants for adolescent girls, pregnant and lactating women, women going through menopause and for male and female reproductive health.
Nikhil Chopra, Head India Business, Cipla Limited, said: "We are focused on strengthening our play in the women’s health segment by amplifying our four-decade long presence in this category. Through this newly acquired portfolio, we shall be catering to a wide range of patient needs including nutritional deficiencies, bone health and sexual health”.
As per (IQVIA MAT Dec’19), the above molecules previously commercialized by Wanbury Ltd have a market size of INR 3,100 Cr in India with sales value of INR 59.6 Cr.